scholarly journals COVID-19 related lockdown: a trigger from the pre-melancholic phase to catatonia and depression, a case report of a 59 year-old man

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Giuseppe Sarli ◽  
Lorenzo Polidori ◽  
David Lester ◽  
Maurizio Pompili
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Depressive Disorder ◽  
Depressive Disorders ◽  
Personality Structure ◽  
Major Depressive ◽  
Psychological Implication ◽  
Major Depressive Disorders ◽  
Psychotic Behavior ◽  
Desire To Die

Abstract Background The pre-melancholic model described by Tellenbach may provide a common model for understanding the psychological implications of the lockdown. In this case report, we describe a rare catatonic status as a psychological implication linked to the COVID-19 pandemic, a really unique global situation. Case presentation B is a 59 year-old man with mute psychiatric anamnesis whose mother suffered from a major depressive disorder. As the lockdown began, he started to develop concerns about his family’s economic condition. According to his wife, he could see no end to the epidemic and no future at all. Moving from this, he started to show a severe and rapidly progressive depression and to develop mood congruent delusions. In addition, he had increasing anhedonia, apathy, starvation and insomnia. This turned in the end into a catatonic-like state, along with a deep desire to die. Admitted to the psychiatry ward in a state of mutism, he was discharged after 15 days with a diagnosis of “Major depressive disorder, single severe episode with no psychotic behavior”. He was treated with Sertraline, Olanzapine and Lorazepam. Conclusions Our aim is to draw attention to the effect of the lockdown upon a Tellenbach-like personality structure. Identifying this type of pre-morbid personality structure could help clinicians understand and treat some cases of patients with severe major depressive disorders elicited by the COVID-19 pandemic.

Mean Beck Depression Inventory-II Scores of Outpatients with Dysthymic or Recurrent-Episode Major Depressive Disorders

2003 ◽  
Vol 93 (2) ◽  
pp. 507-512 ◽  
Author(s):  
Roberta Ball ◽  
Robert A. Steer
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Beck Depression Inventory ◽  
Depressive Disorders ◽  
Recurrent Episode ◽  
Dysthymic Disorder ◽  
Major Depressive ◽  
Major Depressive Disorders ◽  
The Mean ◽  
Comorbid Depressive Disorder

The Beck Depression Inventory-II, published in 1996, was administered to 100 adult outpatients (Age M = 43.1 yr., SD = 15.6) who were diagnosed with a recurrent-episode Major Depressive Disorder and 100 outpatients (Age M = 42.8 yr., SD = 15.7) who were diagnosed with a Dysthymic Disorder. Each diagnostic group was composed of 50 men and 50 women who did not have a comorbid depressive disorder. The mean Beck Depression Inventory-II total score and the mean number of symptoms endorsed by the outpatients with a Major Depressive Disorder were significantly (ps < .001) higher than those for outpatients with a Dysthymic Disorder. The usefulness of the Beck Depression Inventory–II was discussed in helping clinicians discriminate between these two unipolar disorders.

scholarly journals Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions – Improvement (CGI-S) scale in bipolar and major depressive disorder

2018 ◽  
Vol 53 ◽  
pp. 17-22 ◽  
Author(s):  
M. Mohebbi ◽  
S. Dodd ◽  
O.M. Dean ◽  
M. Berk
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Convergent Validity ◽  
Depressive Disorders ◽  
Symptom Improvement ◽  
Major Depressive ◽  
Global Improvement ◽  
Patient Global Impression ◽  
Major Depressive Disorders ◽  
Patient Centric

AbstractBackground:Concordant with an increased emphasis on consumer engagement, the Patient Global Impression Scale of Improvement (PGI-I) is commonly used as an outcome measure in studies evaluating the efficacy of treatments in medical and psychiatric conditions with subjective symptom domains. The current study evaluated the agreement between PGI-I and Clinician Global Impression Scale of Improvement (CGI-I) ratings and convergent validity of PGI-I among individuals with bipolar or major depressive disorders.Method:Data were derived from three double-blind, placebo-controlled, multicentre studies conducted from 2007 to 2015 among adult individuals (N = 472). Clinicians were asked to rate participants symptoms using the CGI-I as well as severity of depression by the Montgomery-Åsberg Depression (MADRS), quality of life (Q-LES-Q), social and occupational functioning (SOFAS), and functional impairment (LIFE–RIFT). Participants were asked to assess their symptom improvement with the PGI-I. Bland-Altman agreement plots and Intra-class correlations were used to evaluate agreement, and Spearman correlation coefficients were implemented to examine convergent validity. Sub-group analyses for disorder type (bipolar and major depression) were performed.Results:There was high agreement between the PGI-I and CGI-I ratings across follow-up time points (weeks 2, 4, 6, 8, 12, 16, 20, 24, and 28). Similar results were observed in male only and female only data and after adjustment for age and gender. Both PGI-I and CGI-I ratings were robustly positively correlated with MADRS, and LIFE-RIFT and negatively correlated with SOFAS and Q-LES-Q, supporting the convergent validity of the PGI-I. Sub-group analyses for bipolar and major depressive disorder showed similar findings.Conclusion:Our findings support the utility of the PGI-I as a participant rated measure of global improvement among individuals with bipolar or major depressive disorders.

Psychiatric shades of grey: mirtazapine-induced hair discoloration and hair loss

2016 ◽  
Vol 33 (3) ◽  
pp. 175-178 ◽  
Author(s):  
M. Osman ◽  
M. D. McCauley
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Adverse Effects ◽  
Depressive Disorder ◽  
Hair Loss ◽  
Temporal Relationship ◽  
Relevant Literature ◽  
Major Depressive ◽  
Hair Colour ◽  
Medical Reason

IntroductionMirtazapine is indicated in the treatment of major depressive disorder particularly in selective serotonin re-uptake inhibitors resistance. Its effect on hair loss is rare with no previous documented effect on hair colour.MethodReview of relevant literature and description of a case report of a 54-year-old male patient who developed alopecia and hair discoloration after initiation of mirtazapine treatment.ResultsUpon cessation of mirtazapine treatment full restoration of hair colour and regrowth of hair was attained within 10 weeks.DiscussionThere was clear temporal relationship between experiencing hair loss and commencing mirtazapine treatment. No other more likely medical reason to explain such experience was established. A noticeable restoration of the hair colour occurred following mirtazapine cessation.ConclusionMirtazapine is associated with hair discoloration and hair loss. The possibility of such distressing adverse effects needs to be conveyed to patients by clinicians and to be further explored by researchers.

The Unified Protocol for Major Depressive Disorder

2017 ◽  
pp. 67-85
Author(s):  
James F. Boswell ◽  
Laren R. Conklin ◽  
Jennifer M. Oswald ◽  
Matteo Bugatti
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Emotional Disorders ◽  
Clinical Case ◽  
Depressive Disorders ◽  
Major Depressive ◽  
Transdiagnostic Treatment ◽  
Unified Protocol ◽  
High Level ◽  
Future Work

Major depressive disorder (MDD) can be a chronic, debilitating condition that for many individuals waxes and wanes over time. In addition, MDD and other unipolar depressive disorders demonstrate a high level of comorbidity with anxiety disorders. This chapter describes the application of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to MDD and other unipolar depressive disorders. We first review research supporting the association between depression and higher-order constructs such as neuroticism. Next, we present a clinical case that, combined with module-specific recommendations, further illustrates how UP principles and strategies are implemented in the treatment of primary depression. Finally, we offer recommendations for future work involving the UP for major depression and other depressive disorders.

A further assessment of decision-making in anorexia nervosa

2015 ◽  
Vol 30 (1) ◽  
pp. 121-127 ◽  
Author(s):  
C. Adoue ◽  
I. Jaussent ◽  
E. Olié ◽  
S. Beziat ◽  
F. Van den Eynde ◽  
...  
Keyword(s):  
Decision Making ◽  
Major Depressive Disorder ◽  
Anorexia Nervosa ◽  
Depressive Disorder ◽  
Cognitive Processes ◽  
Depressive Disorders ◽  
Iowa Gambling Task ◽  
Learning Task ◽  
Adult Women ◽  
Major Depressive

AbstractObjective:Anorexia nervosa (AN) may be associated with impaired decision-making. Cognitive processes underlying this impairment remain unclear, mainly because previous assessments of this complex cognitive function were completed with a single test. Furthermore, clinical features such as mood status may impact this association. We aim to further explore the hypothesis of altered decision-making in AN.Method:Sixty-three adult women with AN and 49 female controls completed a clinical assessment and were assessed by three tasks related to decision-making [Iowa Gambling Task (IGT), Balloon Analogue Risk Task (BART), Probabilistic Reversal Learning Task (PRLT)].Results:People with AN had poorer performance on the IGT and made less risky choices on the BART, whereas performances were not different on PRLT. Notably, AN patients with a current major depressive disorder showed similar performance to those with no current major depressive disorder.Conclusion:These results tend to confirm an impaired decision making-process in people with AN and suggest that various cognitive processes such as inhibition to risk-taking or intolerance of uncertainty may underlie this condition Furthermore, these impairments seem unrelated to the potential co-occurent major depressive disorders.

Brain Biopsy Findings Link Major Depressive Disorder to Neuroinflammation, Oxidative Stress, and Neurovascular Dysfunction: A Case Report

2014 ◽  
Vol 75 (12) ◽  
pp. e23-e26 ◽  
Author(s):  
Souhel Najjar ◽  
Daniel M. Pearlman ◽  
Scott Hirsch ◽  
Kent Friedman ◽  
John Strange ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Major Depressive Disorder ◽  
Case Report ◽  
Depressive Disorder ◽  
Brain Biopsy ◽  
Major Depressive ◽  
Neurovascular Dysfunction
Sign in / Sign up

Export Citation Format

Share Document